13 startups proceed to the Regional Selection of EIT Health Catapult

EIT Health Germany has selected 13 startups to continue their EIT Health Catapult journey and compete in the Regional Selection, where an expert jury will select 2 best-of-the-best business concepts from each category: MedTech, Biotech and Digital Health.

EIT Health Catapult is a training and competition programme that boosts the development of top-notch European health start-ups (Biotech, MedTech and Digital Health) through exposure to leading experts and international investors.

Following the evaluation process, EIT Health Germany has selected 13 shortlisted startups from Germany, Switzerland and Austria for the Regional Selection of this year’s EIT Health Catapult.

The 13 startups will present their projects in an online pitch competition on 26 May 2020 and will be intensively examined by a jury of experts for their investment readiness.

The 6 startups that will be selected by the jury, 2 in each category, will take part to the Catapult semifinals in autumn and will be announced on our website on 26 May in the afternoon.

List of shortlisted startups:

Aidhere – Aidhere is developing a data-driven, stepped-care digital obesity treatment that combines hardware, software and coaching to create an individualised programme that meets medical guidelines.

Amparo – Amparo’s vision is to empower 90% of the world’s 30 million amputees, giving them access to affordable, high-quality prosthetics. Amparo’s revolutionary prosthetic socket solution is the fastest, easiest and most affordable on the market.

Beo Therapeutics – Beo Therapeutics develops oral microbiome therapies that counteract diseases caused by modern lifestyle such as gout, hypertension and chronic kidney disease.

Biotx.ai – Biotx.ai delivers predictive biomarkers as a basis for decision support in precision medicine, using novel, state of the art, machine learning approaches specifically designed to find complex patterns in biomedical data.

CardiLink – CardiLink enables remote monitoring of service-intensive, distributed medical devices.

denovoMATRIX – denovoMATRIX designs and manufactures biomaterials which address the key challenges of manufacturing stem cell based therapies.

Deepc.ai – Deepc.ai uses state-of-the-art ML learning technologies to unlock big amounts of data and solve the biggest challenges in healthcare diagnostics.

InLine-Med– InLine-Med combines intelligent positioning algorithms, innovative surgical guidance and optimized biopsy needles to increase efficiency, accuracy and safety during cancer diagnosis (biopsy), cancer treatment (thermal therapy) and pain therapy.

LenioBio – LenioBio is a protein expression platform company committed to the advancement of transformative technology for the discovery, development, and large-scale production of proteins, unconstrained by the limitations of the cell.

LivingBrain – Living Brain uses their experience to focus their Virtual Reality based cognitive training, their medical software and their knowledge to help millions of people worldwide to achieve a more fulfilled and happier life for patients, decreased recovery time and support research companies gaining new insights in neuro-rehabilitation.

Mediaire: Mediaire empowers radiologists by developing AI-based software which complement the work of the radiologists like performing time consuming and tedious tasks and improving the overall efficiency and diagnostic quality with augmented intelligence. The ultimate goal of the company is to revolutionise the daily life of radiologists through a unique software powered by AI.

PhagoMed – PhagoMed Biopharma is a biotech company focused on the development of innovative, phage-based treatments against persistent bacterial infections and microbiome dysbiosis. PhagoMed has three active development programs in the fields of bacterial vaginosis, implant associated infections and urinary tract infections.

Peragraft – Peragraft aims to develop and produce patient individualised implants for cardiovascular applications.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.